Cracking prostate cancer's code: An enzyme's central role in controlling subtypes and improving therapeutic response

A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at EPFL, and Eneda Toska at Johns Hopkins University have identified the enzyme KMT2D as a key epigenetic regulator in…

Continue Reading

News Source: medicalxpress.com